Shoichi Iriguchi
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shoichi Iriguchi.
Stem cell reports | 2016
Shuichi Kitayama; Rong Zhang; Tianyi Liu; Norihiro Ueda; Shoichi Iriguchi; Yutaka Yasui; Yohei Kawai; Minako Tatsumi; Norihito Hirai; Yasutaka Mizoro; Tatsuaki Iwama; Akira Watanabe; Mahito Nakanishi; Kiyotaka Kuzushima; Yasushi Uemura; Shin Kaneko
Vα24 invariant natural killer T (iNKT) cells are a subset of T lymphocytes implicated in the regulation of broad immune responses. They recognize lipid antigens presented by CD1d on antigen-presenting cells and induce both innate and adaptive immune responses, which enhance effective immunity against cancer. Conversely, reduced iNKT cell numbers and function have been observed in many patients with cancer. To recover these numbers, we reprogrammed human iNKT cells to pluripotency and then re-differentiated them into regenerated iNKT cells in vitro through an IL-7/IL-15-based optimized cytokine combination. The re-differentiated iNKT cells showed proliferation and IFN-γ production in response to α-galactosylceramide, induced dendritic cell maturation and downstream activation of both cytotoxic T lymphocytes and NK cells, and exhibited NKG2D- and DNAM-1-mediated NK cell-like cytotoxicity against cancer cell lines. The immunological features of re-differentiated iNKT cells and their unlimited availability from induced pluripotent stem cells offer a potentially effective immunotherapy against cancer.
Seminars in Immunology | 2016
Peter Karagiannis; Shoichi Iriguchi; Shin Kaneko
Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state from which they can then be differentiated into any cell type of the body. This ability has tremendous implications on a wide number of medical sciences and applications, including cancer treatments. In many cancer patients, tumor infiltrating lymphocytes (TILs) have reached an exhausted state and are unable to exert effector function despite detecting and localizing at the tumor. Although the isolation, ex vivo expansion and transplantation of TILs is effective in a significant group of patients, too many patients do not respond positively to this treatment, in part because the expanded TIL population does not include a sufficient number of cells with the naïve or memory phenotype. Cell reprogramming using iPSC technologies aims to overcome this problem by returning TILs to the pluripotent state from which they can be differentiated into a heterogeneous population of T cells that are best suited to combat the tumor.
Blood | 2015
Shoichi Iriguchi; Norihiro Kikuchi; Shin Kaneko; Yuko Morishima; Masashi Matsuyama; Keigyou Yoh; Satoru Takahashi; Hiromitsu Nakauchi; Yukio Ishii
Although overexpression of T-bet, a master transcription factor in type-1 helper T lymphocytes, has been reported in several hematologic and immune diseases, its role in their pathogenesis is not fully understood. In the present study, we used transgenic model mice (T-bet(tg/wt) and T-bet(tg/tg)) to investigate the effects of T-bet overexpression selectively in T lymphocytes on the development of hematologic and immune diseases. The results showed that T-bet overexpression in T cells spontaneously induced maturation arrest in the mononuclear phagocyte lineage, as well as spontaneous dermatitis and pulmonary alveolar proteinosis (PAP)-like disease in T-bet(tg/wt) and T-bet(tg/tg) mice, respectively. T-bet(tg/tg) alveoli with the PAP phenotype showed remarkable reorganization of alveolar mononuclear phagocyte subpopulations and impaired function, in addition to augmented T-cell infiltration. In addition, PAP development in T-bet(tg/tg) mice was found to be associated with increased migration of myeloid cells from the bone marrow into the peripheral blood. These findings reveal an unexpected link between T-bet overexpression in T lymphocytes and the development of PAP caused by reorganization of mononuclear phagocytes in the lung, and provide new insight into the molecular pathogenesis of secondary PAP accompanied by hematologic disorders.
Stem cell reports | 2018
Norihiro Ueda; Yasushi Uemura; Rong Zhang; Shuichi Kitayama; Shoichi Iriguchi; Yohei Kawai; Yutaka Yasui; Minako Tatsumi; Tatsuki Ueda; Tianyi Liu; Yasutaka Mizoro; Chihiro Okada; Akira Watanabe; Mahito Nakanishi; Satoru Senju; Yasuharu Nishimura; Kiyotaka Kuzushima; Hitoshi Kiyoi; Tomoki Naoe; Shin Kaneko
Summary CD4+ T helper (Th) cell activation is essential for inducing cytotoxic T lymphocyte (CTL) responses against malignancy. We reprogrammed a Th clone specific for chronic myelogenous leukemia (CML)-derived b3a2 peptide to pluripotency and re-differentiated the cells into original TCR-expressing T-lineage cells (iPS-T cells) with gene expression patterns resembling those of group 1 innate lymphoid cells. CD4 gene transduction into iPS-T cells enhanced b3a2 peptide-specific responses via b3a2 peptide-specific TCR. iPS-T cells upregulated CD40 ligand (CD40L) expression in response to interleukin-2 and interleukin-15. In the presence of Wilms tumor 1 (WT1) peptide, antigen-specific dendritic cells (DCs) conditioned by CD4-modified CD40Lhigh iPS-T cells stimulated WT1-specific CTL priming, which eliminated WT1 peptide-expressing CML cells in vitro and in vivo. Thus, CD4 modification of CD40Lhigh iPS-T cells generates innate lymphoid helper-like cells inducing bcr-abl-specific TCR signaling that mediates effectiveanti-leukemic CTL responses via DC maturation, showing potential for adjuvant immunotherapy against leukemia.
Molecular therapy. Nucleic acids | 2018
Kei Higaki; Masako Hirao; Ai Kawana-Tachikawa; Shoichi Iriguchi; Ayako Kumagai; Norihiro Ueda; Wang Bo; Sanae Kamibayashi; Akira Watanabe; Hiromitsu Nakauchi; Kazuo Suzuki; Shin Kaneko
Highly active antiretroviral therapy (HAART) has markedly prolonged the prognosis of HIV-1 patients. However, lifelong dependency on HAART is a continuing challenge, and an effective therapeutic is much desired. Recently, introduction of short hairpin RNA (shRNA) targeting the HIV-1 promoter was found to suppress HIV-1 replication via transcriptional gene silencing (TGS). The technology is expected to be applied with hemato-lymphopoietic cell transplantation of HIV patients to suppress HIV transcription in transplanted hemato-lymphopoietic cells. Combination of the TGS technology with new cell transplantation strategy with induced pluripotent stem cell (iPSC)-derived hemato-lymphopoietic cells might contribute to new gene therapy in the HIV field. In this study, we evaluated iPSC-derived macrophage functions and feasibility of TGS technology in macrophages. Human iPSCs were transduced with shRNAs targeting the HIV-1 promoter region (shPromA) by using a lentiviral vector. The shPromA-transfected iPSCs were successfully differentiated into functional macrophages, and they exhibited strong protection against HIV-1 replication with alteration in the histone structure of the HIV-1 promoter region to induce heterochromatin formation. These results indicated that iPS-derived macrophage is a useful tool to investigate HIV infection and protection, and that the TGS technology targeting the HIV promoter is a potential candidate of new gene therapy.
Archive | 2015
Shoichi Iriguchi; Tomoyuki Yamaguchi; Hiromitsu Nakauchi
Circulating tumor cells (CTCs) or fetal nucleated erythrocytes in maternal peripheral blood are extremely rare cell population (~ 1/105) in circulating blood, though these cells are useful for diagnose diseases. Flow cytometry enabled us to detect such a rare cell populations. However, in order to sort those rare cell populations by fluorescent activated cell sorter (FACS), it is necessary to stain the cells with fluorescent conjugated antibody ex vivo and to obtain theoretically few-hundred milliliters of blood. Therefore, high-speed closed system for analysis and isolation of rare cell populations within the blood without cell staining is desirable. In this chapter, we described analysis of physical characteristic of hematopoietic cells by microfluidics-based devices for efficient detection of rare cell population in circulating blood.
Cell Stem Cell | 2013
Toshinobu Nishimura; Shin Kaneko; Ai Kawana-Tachikawa; Yoko Tajima; Haruo Goto; Dayong Zhu; Kaori Nakayama-Hosoya; Shoichi Iriguchi; Yasushi Uemura; Takafumi Shimizu; Naoya Takayama; Daisuke Yamada; Ken Nishimura; Manami Ohtaka; Nobukazu Watanabe; Satoshi Takahashi; Aikichi Iwamoto; Haruhiko Koseki; Mahito Nakanishi; Koji Eto; Hiromitsu Nakauchi
Blood | 2010
Toshinobu Nishimura; Shin Kaneko; Haruo Gotoh; Naoya Takayama; Takafumi Shimizu; Shoichi Iriguchi; Yoko Tajima; Yutaka Yasui; Nobukazu Watanabe; Satoshi Takahashi; Koji Eto; Hiromitsu Nakauchi
Cancer Research | 2018
Tatsuki Ueda; Shoichi Iriguchi; Yohei Kawai; Atsutaka Minagawa; Hiroyuki Miyoshi; Seitaro Terakura; Yasushi Uemura; Knut Woltjen; Yuzo Kodama; Hiroshi Seno; Yasumichi Hitoshi; Tetsuya Nakatsura; Koji Tamada; Shin Kaneko
Archive | 2017
Shin Kaneko; 金子 新; Yutaka Yasui; 安井 裕; Shoichi Iriguchi; 入口 翔一; Tatsuki Ueda; 上田 樹
Collaboration
Dive into the Shoichi Iriguchi's collaboration.
National Institute of Advanced Industrial Science and Technology
View shared research outputs